🇺🇸 Potassium Canrenoate in United States

476 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 476

Most-reported reactions

1. Acute Kidney Injury — 70 reports (14.71%)
2. Dyspnoea — 62 reports (13.03%)
3. Hyperkalaemia — 48 reports (10.08%)
4. Toxicity To Various Agents — 47 reports (9.87%)
5. Asthenia — 46 reports (9.66%)
6. Drug Interaction — 44 reports (9.24%)
7. Hypotension — 44 reports (9.24%)
8. Lactic Acidosis — 40 reports (8.4%)
9. Anaemia — 38 reports (7.98%)
10. Nausea — 37 reports (7.77%)

Source database →

Frequently asked questions

Is Potassium Canrenoate approved in United States?

Potassium Canrenoate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Potassium Canrenoate in United States?

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the originator. The local marketing authorisation holder may differ — check the official source linked above.